. 2021 Mar 31;19:132. doi: 10.1186/s12967-021-02798-2

Table 4.

Association between IgG and/or IgM seropositivity and clinical variables

Main features	IgG and/or IgM+	IgG and IgM−	n	p-value*	OR	95% CI
Gender
Male	11	350	885	0.01	0.41	0.21–0.82
Female	37	487	885	0.01	0.41	0.21–0.82
Age (years)
< 70	31	579	885	n.s	1.23	0.67–2.26
≥ 70	17	258	885	n.s	1.23	0.67–2.26
Cancer stage
0–III	12	123	804	0.04	0.48	0.24–0.97
IV	30	639	804	0.04	0.48	0.24–0.97
ECOG performance status
0	25	484	793	n.s	1.16	0.61–2.20
1–4	16	268	793	n.s	1.16	0.61–2.20
Lymphopenia
Yes	5	87	755	n.s	1.06	0.41–2.79
No	34	629	755	n.s	1.06	0.41–2.79
Leukopenia
Yes	6	85	764	n.s	1.38	0.56–3.36
No	33	640	764	n.s	1.38	0.56–3.36

n number of patients, OR odds ratio, n.s not statistically significant

*The p-values represent χ² tests of independence indicating associations between SARS-CoV-2 IgG and/or IgM seropositivity and categorical clinical variables (statistically significant p < 0.05)